166 related articles for article (PubMed ID: 19231005)
1. Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection.
Kim KA; Lin W; Tai AW; Shao RX; Weinberg E; De Sa Borges CB; Bhan AK; Zheng H; Kamegaya Y; Chung RT
J Hepatol; 2009 Apr; 50(4):705-11. PubMed ID: 19231005
[TBL] [Abstract][Full Text] [Related]
2. The role of hepatic expression of STAT1, SOCS3 and PIAS1 in the response of chronic hepatitis C patients to therapy.
El-Saadany S; Ziada DH; El Bassat H; Farrag W; El-Serogy H; Eid M; Abdallah M; Ghazy M; Salem HA
Can J Gastroenterol; 2013 Feb; 27(2):e13-7. PubMed ID: 23472246
[TBL] [Abstract][Full Text] [Related]
3. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C.
Persico M; Capasso M; Russo R; Persico E; Crocè L; Tiribelli C; Iolascon A
Gut; 2008 Apr; 57(4):507-15. PubMed ID: 17881539
[TBL] [Abstract][Full Text] [Related]
4. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy.
Persico M; Capasso M; Persico E; Svelto M; Russo R; Spano D; Crocè L; La Mura V; Moschella F; Masutti F; Torella R; Tiribelli C; Iolascon A
Hepatology; 2007 Oct; 46(4):1009-15. PubMed ID: 17668875
[TBL] [Abstract][Full Text] [Related]
5. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE
Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039
[TBL] [Abstract][Full Text] [Related]
6. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C.
Huang Y; Feld JJ; Sapp RK; Nanda S; Lin JH; Blatt LM; Fried MW; Murthy K; Liang TJ
Gastroenterology; 2007 Feb; 132(2):733-44. PubMed ID: 17258724
[TBL] [Abstract][Full Text] [Related]
7. Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C.
Honda M; Takehana K; Sakai A; Tagata Y; Shirasaki T; Nishitani S; Muramatsu T; Yamashita T; Nakamoto Y; Mizukoshi E; Sakai Y; Yamashita T; Nakamura M; Shimakami T; Yi M; Lemon SM; Suzuki T; Wakita T; Kaneko S;
Gastroenterology; 2011 Jul; 141(1):128-40, 140.e1-2. PubMed ID: 21458454
[TBL] [Abstract][Full Text] [Related]
8. Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection.
Satapathy SK; Lingisetty CS; Proper S; Chaudhari S; Williams S
J Clin Gastroenterol; 2010 Feb; 44(2):140-5. PubMed ID: 19826275
[TBL] [Abstract][Full Text] [Related]
9. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
Dore GJ; Torriani FJ; Rodriguez-Torres M; Bräu N; Sulkowski M; Lamoglia RS; Tural C; Clumeck N; Nelson MR; Mendes-Correa MC; Godofsky EW; Dieterich DT; Yetzer E; Lissen E; Cooper DA
AIDS; 2007 Jul; 21(12):1555-9. PubMed ID: 17630550
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
[TBL] [Abstract][Full Text] [Related]
11. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
12. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.
Rodriguez-Torres M; Stoehr A; Gane EJ; Serfaty L; Lawitz E; Zhou A; Bourque M; Bhanja S; Strizki J; Barnard RJ; Hwang PM; DiNubile MJ; Mobashery N
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1029-37.e5. PubMed ID: 24120953
[TBL] [Abstract][Full Text] [Related]
13. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.
Reiberger T; Aberle JH; Kundi M; Kohrgruber N; Rieger A; Gangl A; Holzmann H; Peck-Radosavljevic M
Antivir Ther; 2008; 13(8):969-76. PubMed ID: 19195322
[TBL] [Abstract][Full Text] [Related]
14. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
[TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
[TBL] [Abstract][Full Text] [Related]
16. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
17. Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients.
Ioannou GN; Scott JD; Yang Y; Green PK; Beste LA
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1373-84. PubMed ID: 24127691
[TBL] [Abstract][Full Text] [Related]
18. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
Selvapatt N; Habibi MS; Brown A
J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
[TBL] [Abstract][Full Text] [Related]
19. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
Van den Eynde E; Crespo M; Esteban JI; Jardi R; Ribera E; Carbonell J; Rodríguez-Frias F; Falco V; Curran A; Imaz A; Villar del Saz S; Ocaña I; Esteban R; Pahissa A
Clin Infect Dis; 2009 Apr; 48(8):1152-9. PubMed ID: 19275492
[TBL] [Abstract][Full Text] [Related]
20. Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner.
Shao RX; Zhang L; Peng LF; Sun E; Chung WJ; Jang JY; Tsai WL; Hyppolite G; Chung RT
J Virol; 2010 Jun; 84(12):6060-9. PubMed ID: 20375166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]